Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
NCT00262236 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 693
Last updated 2016-11-18
Summary
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
Conditions
Interventions
- DRUG
-
Aliskiren
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceutical · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-11-30
- Primary Completion
- 2006-08-31
- Completion
- 2006-08-31
Countries
- Germany
- Switzerland
Study Locations
More Related Trials
-
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
NCT00219024 ·Status: COMPLETED ·Phase: PHASE3
-
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
NCT00402103 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
NCT00777946 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
NCT00778921 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01113047 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
NCT00219167 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
NCT00667719 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
NCT00219050 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
NCT00841672 ·Status: COMPLETED ·Phase: PHASE3
-
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
NCT00809926 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00765947 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
NCT00171405 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00654875 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
NCT00867490 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
NCT01922141 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
NCT00219193 ·Status: COMPLETED ·Phase: PHASE3
-
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
NCT00760266 ·Status: COMPLETED ·Phase: PHASE4
-
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
NCT00219037 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
NCT00765674 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
NCT00705575 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
NCT00927394 ·Status: COMPLETED ·Phase: PHASE4